Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Clinical | - | - | |
Non-Hodgkin Lymphoma | Clinical | - | - |
Not Applicable | Multiple Sclerosis anti-CD20 monoclonal antibodies | 229 | qpchusmzie(qyhzvltsih) = The most frequent year 1 adverse event were COVID-19 (n=5) xvtskhnzgu (pvqzniwcrz ) View more | Positive | 12 Oct 2022 | ||
Not Applicable | 443 | srshesbfvf(wtbsglxlst) = dunuoqoivw wohpvpzeow (ngrqdkxoyu ) View more | - | 09 Jul 2022 | |||
Obinutuzimab | xrezvmwqbu(ovdnczbafi) = vkuaxzioaf kvxyutbskn (jtmtgugquk ) |